Review
. 2020 Aug;10(3).
doi: 10.3390/jpm10030098.

Circulating MicroRNAs as Prognostic and Therapeutic Biomarkers in Breast Cancer Molecular Subtypes

Veronica Zelli 1 Chiara Compagnoni 1 Roberta Capelli 1 Katia Cannita 2 Tina Sidoni 2 Corrado Ficorella 2 Carlo Capalbo 3 Francesca Zazzeroni 1 Alessandra Tessitore 1 Edoardo Alesse 1 
Affiliations
  • PMID: 32842653
  •     88 References

Abstract

Breast cancer (BC) is a common and heterogeneous disease, of which six molecular subtypes, characterized by different biological features and clinical outcomes, were described. The identification of additional biomarkers able to further connote and distinguish the different BC subtypes is essential to improve the diagnostic, prognostic and therapeutic strategies in BC patients. MicroRNAs (miRNAs) are short non-coding RNA involved in several physiological and pathological processes, including cancer development and progression. In particular, circulating miRNAs, which can be found in an adequately stable structure in serum/plasma of cancer patients, are emerging as very promising non-invasive biomarkers. Several studies have analyzed the potential role of circulating miRNAs as prognostic and therapeutic markers in BC. In the present review we describe circulating miRNAs, identified as putative biomarker in BC, with special reference to different BC molecular subtypes.

Keywords: biomarkers; breast cancer; circulating microRNA; microRNA; molecular subtypes.

Role of miR-21 as an authentic oncogene in mediating drug resistance in breast cancer.
Shiva Najjary, Reza Mohammadzadeh, +3 authors, Behzad Baradaran.
Gene, 2020 Feb 09; 738. PMID: 32035242
Review.
microRNA expression profiling on individual breast cancer patients identifies novel panel of circulating microRNA for early detection.
Rimi Hamam, Arwa M Ali, +4 authors, Nehad M Alajez.
Sci Rep, 2016 May 18; 6. PMID: 27180809    Free PMC article.
miRNAs and regulation of cell signaling.
Atsuhiko Ichimura, Yoshinao Ruike, Kazuya Terasawa, Gozoh Tsujimoto.
FEBS J, 2011 Mar 15; 278(10). PMID: 21395975
Review.
The current state of breast cancer classification.
G Viale.
Ann Oncol, 2012 Sep 26; 23 Suppl 10. PMID: 22987963
Prospective Assessment of Systemic MicroRNAs as Markers of Response to Neoadjuvant Chemotherapy in Breast Cancer.
Andrew McGuire, Maire-Caitlin Casey, +11 authors, Michael J Kerin.
Cancers (Basel), 2020 Jul 11; 12(7). PMID: 32645898    Free PMC article.
Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR).
Evan M Kroh, Rachael K Parkin, Patrick S Mitchell, Muneesh Tewari.
Methods, 2010 Feb 12; 50(4). PMID: 20146939    Free PMC article.
Highly Cited.
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.
Joseph A Sparano, Robert J Gray, +27 authors, George W Sledge.
N Engl J Med, 2019 Jun 04; 380(25). PMID: 31157962    Free PMC article.
Highly Cited.
Epigenetic silencing of ITGA2 by MiR-373 promotes cell migration in breast cancer.
Wen Ding, Xiao-Lu Fan, +6 authors, Guang-Rong Yan.
PLoS One, 2015 Aug 11; 10(8). PMID: 26258411    Free PMC article.
Circulating microRNAs in breast cancer: novel diagnostic and prognostic biomarkers.
Rimi Hamam, Dana Hamam, +5 authors, Nehad M Alajez.
Cell Death Dis, 2017 Sep 08; 8(9). PMID: 28880270    Free PMC article.
Highly Cited. Review.
Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial.
Volkmar Müller, Stephan Gade, +10 authors, Heidi Schwarzenbach.
Breast Cancer Res Treat, 2014 Aug 05; 147(1). PMID: 25086636
Circulating microRNAs miR-331 and miR-195 differentiate local luminal a from metastatic breast cancer.
Peter McAnena, Kahraman Tanriverdi, +4 authors, Michael J Kerin.
BMC Cancer, 2019 May 12; 19(1). PMID: 31077182    Free PMC article.
An update review of deregulated tumor suppressive microRNAs and their contribution in various molecular subtypes of breast cancer.
Narges Dastmalchi, Reza Safaralizadeh, +2 authors, Amir Baghbanzadeh.
Gene, 2019 Dec 31; 729. PMID: 31884105
Review.
Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy.
Alba Rodríguez-Martínez, Diego de Miguel-Pérez, +11 authors, María José Serrano.
Breast Cancer Res, 2019 Feb 08; 21(1). PMID: 30728048    Free PMC article.
Identification of Breast Cancer Subtype Specific MicroRNAs Using Survival Analysis to Find Their Role in Transcriptomic Regulation.
Michał Denkiewicz, Indrajit Saha, +2 authors, Dariusz Plewczynski.
Front Genet, 2019 Dec 05; 10. PMID: 31798622    Free PMC article.
Branched rolling circle amplification method for measuring serum circulating microRNA levels for early breast cancer detection.
Tingting Fan, Yu Mao, +5 authors, Yuyang Jiang.
Cancer Sci, 2018 Jul 08; 109(9). PMID: 29981251    Free PMC article.
Serum microRNA-21 predicted treatment outcome and survival in HER2-positive breast cancer patients receiving neoadjuvant chemotherapy combined with trastuzumab.
Baoquan Liu, Fei Su, +4 authors, Jianguo Zhang.
Cancer Chemother Pharmacol, 2019 Sep 05; 84(5). PMID: 31482230
Circulating MicroRNAs in Cancer: Potential and Challenge.
Mengying Cui, Hongdan Wang, +4 authors, Xuewen Zhang.
Front Genet, 2019 Aug 06; 10. PMID: 31379918    Free PMC article.
Highly Cited. Review.
Expanding roles for miRNAs and siRNAs in cell regulation.
Kenji Nakahara, Richard W Carthew.
Curr Opin Cell Biol, 2004 Jun 16; 16(2). PMID: 15196554
Review.
Repeated observation of breast tumor subtypes in independent gene expression data sets.
Therese Sorlie, Robert Tibshirani, +13 authors, David Botstein.
Proc Natl Acad Sci U S A, 2003 Jun 28; 100(14). PMID: 12829800    Free PMC article.
Highly Cited.
MiRNAs as Potential Prognostic Biomarkers for Metastasis in Thin and Thick Primary Cutaneous Melanomas.
Virginia Valentini, Veronica Zelli, +10 authors, Antonio Giovanni Richetta.
Anticancer Res, 2019 Aug 02; 39(8). PMID: 31366492
Gene expression profiling predicts clinical outcome of breast cancer.
Laura J van 't Veer, Hongyue Dai, +13 authors, Stephen H Friend.
Nature, 2002 Feb 02; 415(6871). PMID: 11823860
Highly Cited.
Predictive and Prognostic Value of Selected MicroRNAs in Luminal Breast Cancer.
Maria Amorim, João Lobo, +8 authors, Carmen Jerónimo.
Front Genet, 2019 Oct 02; 10. PMID: 31572437    Free PMC article.
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases.
Rajesha Rupaimoole, Frank J Slack.
Nat Rev Drug Discov, 2017 Feb 18; 16(3). PMID: 28209991
Highly Cited. Review.
Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma.
Jason D Arroyo, John R Chevillet, +9 authors, Muneesh Tewari.
Proc Natl Acad Sci U S A, 2011 Mar 09; 108(12). PMID: 21383194    Free PMC article.
Highly Cited.
Epigenetically altered miR‑193a‑3p promotes HER2 positive breast cancer aggressiveness by targeting GRB7.
Yiyin Tang, Siyuan Yang, +4 authors, Qian Zhang.
Int J Mol Med, 2019 Apr 25; 43(6). PMID: 31017268    Free PMC article.
Characterisation of multifocal breast cancer using the 70-gene signature in clinical low-risk patients enrolled in the EORTC 10041/BIG 03-04 MINDACT trial.
K C Aalders, A Kuijer, +12 authors, TRANSBIG Consortium and the MINDACT Investigators.
Eur J Cancer, 2017 May 10; 79. PMID: 28477490
Robust expression of tumor suppressor miRNA's let-7 and miR-195 detected in plasma of Saudi female breast cancer patients.
Amal Qattan, Haya Intabli, +3 authors, Suad Bin Amer.
BMC Cancer, 2017 Dec 01; 17(1). PMID: 29183284    Free PMC article.
Molecular portraits of human breast tumours.
C M Perou, T Sørlie, +15 authors, D Botstein.
Nature, 2000 Aug 30; 406(6797). PMID: 10963602
Highly Cited.
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer.
Aleix Prat, Joel S Parker, +5 authors, Charles M Perou.
Breast Cancer Res, 2010 Sep 04; 12(5). PMID: 20813035    Free PMC article.
Highly Cited.
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
Fatima Cardoso, Laura J van't Veer, +32 authors, MINDACT Investigators.
N Engl J Med, 2016 Aug 25; 375(8). PMID: 27557300
Highly Cited.
Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease?
Esther E Creemers, Anke J Tijsen, Yigal M Pinto.
Circ Res, 2012 Feb 04; 110(3). PMID: 22302755
Highly Cited. Review.
Circulating miR-19a and miR-205 in serum may predict the sensitivity of luminal A subtype of breast cancer patients to neoadjuvant chemotherapy with epirubicin plus paclitaxel.
Qian Li, Mei Liu, +5 authors, Binghe Xu.
PLoS One, 2014 Aug 20; 9(8). PMID: 25137071    Free PMC article.
Plasma miR-21, miR-155, miR-10b, and Let-7a as the potential biomarkers for the monitoring of breast cancer patients.
Solmaz Khalighfard, Ali Mohammad Alizadeh, Shiva Irani, Ramesh Omranipour.
Sci Rep, 2018 Dec 21; 8(1). PMID: 30568292    Free PMC article.
Reproductive risk factors in relation to molecular subtypes of breast cancer: Results from the nurses' health studies.
Julia S Sisti, Laura C Collins, +3 authors, A Heather Eliassen.
Int J Cancer, 2015 Dec 20; 138(10). PMID: 26684063    Free PMC article.
Circulating non‑coding RNA‑biomarker potential in neoadjuvant chemotherapy of triple negative breast cancer?
Andrea Ritter, Marc Hirschfeld, +8 authors, Thalia Erbes.
Int J Oncol, 2019 Dec 04; 56(1). PMID: 31789396    Free PMC article.
Circulating miR-195 as a Therapeutic Biomarker in Turkish Breast Cancer Patients.
Gulsah Cecene, Secil Ak, +10 authors, Ismet Tasdelen.
Asian Pac J Cancer Prev, 2016 Nov 01; 17(9). PMID: 27797225
MicroRNAs in regulation of triple-negative breast cancer progression.
Dominika Piasecka, Marcin Braun, +2 authors, Hanna Romanska.
J Cancer Res Clin Oncol, 2018 Jun 21; 144(8). PMID: 29923083    Free PMC article.
Review.
MicroRNA-21 as a predictor and prognostic factor for trastuzumab therapy in human epidermal growth factor receptor 2-positive metastatic breast cancer.
Marwa Badr, Hebatallah Said, +3 authors, Mai Atef Abd El Mageed.
J Cell Biochem, 2018 Sep 25; 120(3). PMID: 30246355
Correlation between microRNA-21, microRNA-206 and estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 in breast cancer.
Yuanwen Chen, Nian Wu, +2 authors, Chengyi Wu.
Clin Biochem, 2019 Jul 06; 71. PMID: 31276668
Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients.
Corinna Eichelser, Isabel Stückrath, +4 authors, Heidi Schwarzenbach.
Oncotarget, 2014 Oct 22; 5(20). PMID: 25333260    Free PMC article.
Highly Cited.
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +28 authors, George W Sledge.
N Engl J Med, 2015 Sep 29; 373(21). PMID: 26412349    Free PMC article.
Highly Cited.
A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients.
Huiping Li, Jiang Liu, +15 authors, Erwei Song.
Nat Commun, 2018 Apr 25; 9(1). PMID: 29691399    Free PMC article.
miR-720 is a downstream target of an ADAM8-induced ERK signaling cascade that promotes the migratory and invasive phenotype of triple-negative breast cancer cells.
Sonia G Das, Mathilde Romagnoli, +4 authors, Gail E Sonenshein.
Breast Cancer Res, 2016 Apr 04; 18(1). PMID: 27039296    Free PMC article.
The Emerging Role of MicroRNAs in Breast Cancer.
Zhiguang Yang, Zhaoyu Liu.
J Oncol, 2020 Jul 28; 2020. PMID: 32714393    Free PMC article.
Review.
High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer.
Simone Anfossi, Antonio Giordano, +12 authors, James M Reuben.
PLoS One, 2014 Jan 15; 9(1). PMID: 24416156    Free PMC article.
miR-188-5p suppresses cellular proliferation and migration via IL6ST: A potential noninvasive diagnostic biomarker for breast cancer.
Mei Wang, Huiling Zhang, +7 authors, Wei Zhu.
J Cell Physiol, 2019 Oct 28; 235(5). PMID: 31650530
Therapeutic Use of MicroRNAs in Cancer.
Alessandra Tessitore, Germana Cicciarelli, +7 authors, Edoardo Alesse.
Anticancer Agents Med Chem, 2015 Aug 25; 16(1). PMID: 26299662
Review.
Identification of a circulating microRNA signature to distinguish recurrence in breast cancer patients.
Dezheng Huo, Wendy M Clayton, +2 authors, Olufunmilayo I Olopade.
Oncotarget, 2016 Jul 14; 7(34). PMID: 27409424    Free PMC article.
Inhibition of miRNA-34a promotes triple negative cancer cell proliferation by promoting glucose uptake.
Zhen Li, Xiaoxuan Gong, +5 authors, Jinhai Tang.
Exp Ther Med, 2019 Oct 17; 18(5). PMID: 31616515    Free PMC article.
Circulating microRNAs as potential cancer biomarkers: the advantage and disadvantage.
Hao Wang, Ran Peng, +2 authors, Lixiang Xue.
Clin Epigenetics, 2018 May 02; 10. PMID: 29713393    Free PMC article.
Highly Cited. Review.
Identification of Cell-Free Circulating MicroRNAs for the Detection of Early Breast Cancer and Molecular Subtyping.
Karen C B Souza, Adriane F Evangelista, +8 authors, Marcia M C Marques.
J Oncol, 2019 Sep 06; 2019. PMID: 31485228    Free PMC article.
A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients.
Kristine Kleivi Sahlberg, Giulia Bottai, +4 authors, Libero Santarpia.
Clin Cancer Res, 2014 Dec 31; 21(5). PMID: 25547678
Highly Cited.
Cell-free miRNAs as non-invasive biomarkers in breast cancer: Significance in early diagnosis and metastasis prediction.
Dharambir Kashyap, Harmandeep Kaur.
Life Sci, 2020 Feb 12; 246. PMID: 32044304
Review.
MicroRNA-378-mediated suppression of Runx1 alleviates the aggressive phenotype of triple-negative MDA-MB-231 human breast cancer cells.
Gillian Browne, Julie A Dragon, +10 authors, Jane B Lian.
Tumour Biol, 2016 Jan 11; 37(7). PMID: 26749280    Free PMC article.
MicroRNA-188-5p promotes apoptosis and inhibits cell proliferation of breast cancer cells via the MAPK signaling pathway by targeting Rap2c.
Xinying Zhu, Jinxia Qiu, +7 authors, Changwei Qiu.
J Cell Physiol, 2019 Sep 22; 235(3). PMID: 31541458
Association between mir-24 and mir-378 in formalin-fixed paraffin-embedded tissues of breast cancer.
Jia-Yu Yin, Zhao-Qun Deng, +7 authors, Xiao-Wen Zhu.
Int J Clin Exp Pathol, 2014 Aug 15; 7(7). PMID: 25120807    Free PMC article.
MicroRNA-10b and the clinical outcomes of various cancers: A systematic review and meta-analysis.
Qiangxin Huang, Qian Song, +2 authors, Ludong Liang.
Clin Chim Acta, 2017 Sep 03; 474. PMID: 28864233
Systematic Review.
Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes.
Sasagu Kurozumi, Yuri Yamaguchi, +3 authors, Jun Horiguchi.
J Hum Genet, 2016 Jul 22; 62(1). PMID: 27439682
Review.
An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers.
Rachael Natrajan, Britta Weigelt, +10 authors, Jorge S Reis-Filho.
Breast Cancer Res Treat, 2009 Aug 19; 121(3). PMID: 19688261
Breast cancer.
Nadia Harbeck, Michael Gnant.
Lancet, 2016 Nov 21; 389(10074). PMID: 27865536
Highly Cited. Review.
Serum levels of circulating miRNA-21, miRNA-10b and miRNA-200c in triple-negative breast cancer patients.
Sebastian Niedźwiecki, Janusz Piekarski, +2 authors, Arkadiusz Jeziorski.
Ginekol Pol, 2018 Sep 15; 89(8). PMID: 30215459
Expression pattern of microRNAs related with response to trastuzumab in breast cancer.
Fan Yang, Ziyi Fu, +10 authors, Yongmei Yin.
J Cell Physiol, 2019 Feb 17;. PMID: 30770556
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies.
Koei Chin, Sandy DeVries, +21 authors, Joe W Gray.
Cancer Cell, 2006 Dec 13; 10(6). PMID: 17157792
Highly Cited.
Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management.
Eleni van Schooneveld, Hans Wildiers, +3 authors, Steven J Van Laere.
Breast Cancer Res, 2015 Apr 08; 17. PMID: 25849621    Free PMC article.
Highly Cited. Review.
MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer.
Aoife J Lowery, Nicola Miller, +8 authors, Michael J Kerin.
Breast Cancer Res, 2009 May 13; 11(3). PMID: 19432961    Free PMC article.
Highly Cited.
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, +3 authors, Ahmedin Jemal.
CA Cancer J Clin, 2018 Sep 13; 68(6). PMID: 30207593
Highly Cited.
Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models.
Anna Bergamaschi, Geir Olav Hjortland, +9 authors, Olav Engebraaten.
Mol Oncol, 2009 Aug 29; 3(5-6). PMID: 19713161    Free PMC article.
Circulating microRNAs as stable blood-based markers for cancer detection.
Patrick S Mitchell, Rachael K Parkin, +17 authors, Muneesh Tewari.
Proc Natl Acad Sci U S A, 2008 Jul 30; 105(30). PMID: 18663219    Free PMC article.
Highly Cited.
Clinical potential of miR-940 as a diagnostic and prognostic biomarker in breast cancer patients.
Wenjun Liu, Yongmei Xu, Hongliang Guan, Hongwei Meng.
Cancer Biomark, 2018 May 31; 22(3). PMID: 29843213
MicroRNAs: genomics, biogenesis, mechanism, and function.
David P Bartel.
Cell, 2004 Jan 28; 116(2). PMID: 14744438
Highly Cited. Review.
MicroRNA in breast cancer: The association with BRCA1/2.
Nina Petrovic, Radoslav Davidovic, +2 authors, R Esma Isenovic.
Cancer Biomark, 2017 Jan 28; 19(2). PMID: 28128741
Review.
Identification of miRNAs Enriched in Extracellular Vesicles Derived from Serum Samples of Breast Cancer Patients.
Patricia M M Ozawa, Evelyn Vieira, +15 authors, Enilze M S F Ribeiro.
Biomolecules, 2020 Jan 23; 10(1). PMID: 31963351    Free PMC article.
The Promising Role of miR-21 as a Cancer Biomarker and Its Importance in RNA-Based Therapeutics.
Diana Bautista-Sánchez, Cristian Arriaga-Canon, +8 authors, Luis A Herrera.
Mol Ther Nucleic Acids, 2020 Apr 04; 20. PMID: 32244168    Free PMC article.
Review.
MicroRNA signatures in human cancers.
George A Calin, Carlo M Croce.
Nat Rev Cancer, 2006 Oct 25; 6(11). PMID: 17060945
Highly Cited. Review.
MicroRNA-138 is a Prognostic Biomarker for Triple-Negative Breast Cancer and Promotes Tumorigenesis via TUSC2 repression.
Srikanth Nama, Manish Muhuri, +4 authors, Prabha Sampath.
Sci Rep, 2019 Sep 05; 9(1). PMID: 31481748    Free PMC article.
MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer.
Gloria Bertoli, Claudia Cava, Isabella Castiglioni.
Theranostics, 2015 Jul 23; 5(10). PMID: 26199650    Free PMC article.
Highly Cited. Review.
MicroRNAs in cancer.
Gianpiero Di Leva, Michela Garofalo, Carlo M Croce.
Annu Rev Pathol, 2013 Oct 02; 9. PMID: 24079833    Free PMC article.
Highly Cited. Review.
Detection of microRNA expression in human peripheral blood microvesicles.
Melissa Piper Hunter, Noura Ismail, +10 authors, Clay B Marsh.
PLoS One, 2008 Nov 13; 3(11). PMID: 19002258    Free PMC article.
Highly Cited.
Identification and validation of oncologic miRNA biomarkers for luminal A-like breast cancer.
Ailbhe M McDermott, Nicola Miller, +4 authors, Michael J Kerin.
PLoS One, 2014 Feb 06; 9(1). PMID: 24498016    Free PMC article.
Breast Cancer Molecular Stratification: From Intrinsic Subtypes to Integrative Clusters.
Hege G Russnes, Ole Christian Lingjærde, Anne-Lise Børresen-Dale, Carlos Caldas.
Am J Pathol, 2017 Jul 25; 187(10). PMID: 28733194
Highly Cited. Review.
Refinement of breast cancer molecular classification by miRNA expression profiles.
Rolf Søkilde, Helena Persson, +11 authors, Carlos Rovira.
BMC Genomics, 2019 Jun 19; 20(1). PMID: 31208318    Free PMC article.
Analysis of circulating microRNAs during adjuvant chemotherapy in patients with luminal A breast cancer.
Ebru Esin Yoruker, Fatma Aydoğan, +2 authors, Nejat Dalay.
Mol Clin Oncol, 2015 Jul 15; 3(4). PMID: 26171214    Free PMC article.
Circulating Cell-free miRNA Expression and its Association with Clinicopathologic Features in Inflammatory and Non- Inflammatory Breast Cancer.
K Hamdi, J Blancato, +10 authors, R Marrakchi.
Asian Pac J Cancer Prev, 2016 May 26; 17(4). PMID: 27221856
Identification of Specific miRNA Signature in Paired Sera and Tissue Samples of Indian Women with Triple Negative Breast Cancer.
Seema Thakur, Rajesh K Grover, +2 authors, Bhudev C Das.
PLoS One, 2016 Jul 13; 11(7). PMID: 27404381    Free PMC article.
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.
Christina Curtis, Sohrab P Shah, +29 authors, Samuel Aparicio.
Nature, 2012 Apr 24; 486(7403). PMID: 22522925    Free PMC article.
Highly Cited.
Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression.
Corinna Eichelser, Dieter Flesch-Janys, +2 authors, Heidi Schwarzenbach.
Clin Chem, 2013 Jun 12; 59(10). PMID: 23748853
Novel patterns of genome rearrangement and their association with survival in breast cancer.
James Hicks, Alexander Krasnitz, +20 authors, Anders Zetterberg.
Genome Res, 2006 Dec 05; 16(12). PMID: 17142309    Free PMC article.
Highly Cited.
Serum microRNA expression as an early marker for breast cancer risk in prospectively collected samples from the Sister Study cohort.
Ashley C Godfrey, Zongli Xu, +5 authors, Jack A Taylor.
Breast Cancer Res, 2013 May 28; 15(3). PMID: 23705859    Free PMC article.